Build status - In Progress

A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid

A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid
Recruiting
55 years - 80 years
All
Phase 3
17 participants needed
1 Location

Brief description of study

The Study is two research trials aimed at preventing Alzheimer’s disease (AD) dementia. One is called AHEAD-3 and the other is called AHEAD-45. AHEAD-3 studies people with intermediate amyloid, while AHEAD-45 studies people with elevated amyloid. Research studies are designed to gain scientific knowledge that may help people in the future.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Preclinical Alzheimer's diseaseElevated amyloidEarly preclinical Alzheimer's disease
  • Age: 55 years - 80 years
  • Gender: All

Male or female, age 55 to 80 years inclusive Study Partner

Updated on 04 Aug 2024. Study ID: 842728

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center